http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
-
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
-
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
-
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
-
Agenus to Participate at Upcoming Investor Conferences
-
Agenus to Participate at Upcoming Investor Conferences
-
Agenus (AGEN) Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology
-
Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)
-
Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)
-
Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
-
Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
-
Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment-Resistant Cancers at SITC
-
Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment-Resistant Cancers at SITC
-
Agenus Corporate Update and Third Quarter 2021 Financial Report
-
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
-
Agenus Corporate Update and Third Quarter 2021 Financial Report
-
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
-
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
-
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
-
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
-
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
-
Agenus (AGEN) Withdraws Balstilimab BLA
-
Agenus Provides Update on Balstilimab Development
-
Agenus Provides Update on Balstilimab Development
-
Agenus (AGEN) to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
-
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
-
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
-
Agenus to Present AGEN1181 Clinical Data at SITC
-
Agenus to Present AGEN1181 Clinical Data at SITC
-
Agenus's (AGEN) Phase 2 Data Shows Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer
-
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
-
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
-
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
-
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
-
Agenus to Participate in September Investor Conferences
-
Agenus to Participate in September Investor Conferences
-
Balstilimab Monotherapy Data Published in Gynecologic Oncology
-
Balstilimab Monotherapy Data Published in Gynecologic Oncology
-
Agenus Corporate Update and Second Quarter 2021 Financial Report
-
Agenus Corporate Update and Second Quarter 2021 Financial Report
-
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021
-
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021
-
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
-
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
-
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
-
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
-
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
-
Agenus (AGEN) Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

